Synergistic effects of adjuvants interferon-γ and levamisole on DNA vaccination against infection with newcastle disease virus

Viral Immunology

Volumn 20, Issue 2, 2007, Pages 288-299

  Yin, Jiangmei ^b   Jin, Huali ^b   Yang, Fu ^b   Ding, Zheng ^b   Huang, Chang ^b   Zhu, Qinghong ^b   Wang, Bin ^a  

^a CHINA AGRICULTURAL UNIVERSITY   (China)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; DNA VACCINE; GAMMA INTERFERON; HEMAGGLUTININ; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; LEVAMISOLE; NEWCASTLE DISEASE VACCINE; VIRUS SIALIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIRD DISEASE; CELLULAR IMMUNITY; CHICKEN; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG POTENTIATION; HEMAGGLUTINATION INHIBITION TEST; HUMORAL IMMUNITY; LYMPHOCYTE PROLIFERATION; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; CHICKENS; CYTOKINES; DRUG SYNERGISM; GENETIC VECTORS; HEMAGGLUTINATION INHIBITION TESTS; HN PROTEIN; IMMUNOGLOBULIN G; INTERFERON TYPE II; LEVAMISOLE; LYMPHOCYTE ACTIVATION; NEWCASTLE DISEASE; NEWCASTLE DISEASE VIRUS; VACCINATION; VACCINES, DNA; VIRAL FUSION PROTEINS; VIRAL LOAD; VIRAL VACCINES;

ANIMALIA; GALLUS GALLUS; NEWCASTLE DISEASE VIRUS;

EID: 34447536634     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2006.0108     Document Type: Article

References (44)

1. Amosenko FA, Brzhezovskii VZ, Liubchenko LN, Shabanov MA, Kozlova VM, Vanushko VE, Kazubskaia TP, Gar'kavtseva RF, and Kalinin VN: [Analysis of mutations in the RET proto-oncogene in patients with medullary thyroid tumor]. Genetika 2003;39:847-854.
2. Asif M, Jenkins KA, Hilton LS, Kimpton WG, Bean AG, and Lowenthal JW: Cytokines as adjuvants for avian vaccines. Immunol Cell Biol 2004;82:638-643.
3. Babiuk LA, van Drunen Littel-van den Hurk, and Babiuk SL: Immunization of animals: From DNA to the dinner plate. Vet Immunol Immunopathol 1999;72:189-202.
4. Barteling SJ, and Vreeswijk J: Developments in foot-and-mouth disease vaccines. Vaccine 1991;9:75-88.
5. Boxus M, Letellier C, and Kerkhofs P: Real time RT-PCR for the detection and quantitation of bovine respiratory syncytial virus. J Virol Methods 2005;125:125-130.
6. Davenport FM: Seventeen years' experience with mineral oil adjuvant influenza virus vaccines. Ann Allergy 1968;26:288-292.
7. de Leeuw O, and Peeters B: Complete nucleotide sequence of Newcastle disease virus: Evidence for the existence of a new genus within the subfamily Paramyxovirinae. J Gen Virol 1999;80:131-136.
8. Degen WG, Daal N, Rothwell L, Kaiser P, and Schijns VE: Th1/Th2 polarization by viral and helminth infection in birds. Vet Microbiol 2005;105:163-167.
9. Donnelly JJ, Ulmer JB, Shiver JW, and Liu MA: DNA vaccines. Annu Rev Immunol 1997;15:617-648.
10. Doria-Rose NA, and Haigwood NL: DNA vaccine strategies: Candidates for immune modulation and immunization regimens. Methods 2003;31:207-216.
11. Fukanoki S, Matsumoto K, Mori H, and Takeda R: Relationship between antigen release and antibody response of infectious coryza water-in-oil-in-water emulsion vaccines. Avian Dis 2000;44:869-873.
12. Gould AR, Kattenbelt JA, Selleck P, Hansson E, Della-Porta A, and Westbury HA: Virulent Newcastle disease in Australia: Molecular epidemiological analysis of viruses isolated prior to and during the outbreaks of 1998-2000. Virus Res 2001;77:51-60.
13. Heath AW: Cytokines as immunological adjuvants. Pharm Biotechnol 1995;6:645-658.
14. Heckert RA, Elankumaran S, Oshop GL, and Vakharia VN: A novel transcutaneous plasmid-dimethylsulfoxide delivery technique for avian nucleic acid immunization. Vet Immunol Immunopathol 2002;89:67-81.
15. Hilton LS, Bean AG, and Lowenthal JW: The emerging role of avian cytokines as immunotherapeutics and vaccine adjuvants. Vet Immunol Immunopathol 2002;85:119-128.
16. Jin H, Li Y, Ma Z, Zhang F, Xie Q, Gu D, and Wang B: Effect of chemical adjuvants on DNA vaccination. Vaccine 2004;22:2925-2935.
17. Kang Y, Jin H, Zheng G, Xie Q, Yin J, Yu Y, Xiao C, Zhang X, Chen A, and Wang B: The adjuvant effect of levamisole on killed viral vaccines. Vaccine 2005;23:5543-5550.
18. Kim JJ, Yang JS, Manson KH, and Weiner DB: Modulation of antigen-specific cellular immune responses to DNA vaccination in rhesus macaques through the use of IL-2, IFN-γ, or IL-4 gene adjuvants. Vaccine 2001;19:2496-2505.
19. Laurie JA, Moertel CG, Fleming TR, Wieand HS, Leigh JE, Rubin J, McCormack GW, Gerstner JB, Krook JE, and Malliard J: Surgical adjuvant therapy of large-bowel carcinoma: An evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 1989;7: 1447-1456.
20. Letellier C, Burny A, and Meulemans G: Construction of a pigeonpox virus recombinant: Expression of the Newcastle disease virus (NDV) fusion glycoprotein and protection of chickens against NDV challenge. Arch Virol 1991;118:43-56.
21. Liang R, Cao DJ, Li JQ, Chen J, Guo X, Zhuang FF, and Duan MX: Newcastle disease outbreaks in western China were caused by the genotypes VIIa and VIII. Vet Microbiol 2002;87:193-203.
22. Lindblad EB, Elhay MJ, Silva R, Appelberg R, and Andersen P: Adjuvant modulation of immune responses to tuberculosis subunit vaccines. Infect Immun 1997;65:623-629.
23. Loke CF, Omar AR, Raha AR, and Yusoff K: Improved protection from velogenic Newcastle disease virus challenge following multiple immunizations with plasmid DNA encoding for F and HN genes. Vet Immunol Immunopathol 2005;106:259-267.
24. Lowenthal JW, Lambrecht B, van den Berg TP, Andrew ME, Strom AD, and Bean AG: Avian cytokines: The natural approach to therapeutics. Dev Comp Immunol 2000;24:355-365.
25. Lowenthal JW, O'Neil TE, Broadway M, Strom AD, Digby MR, Andrew M, and York JJ: Coadministration of IFN-γ enhances antibody responses in chickens. J Interferon Cytokine Res 1998;18:617-622.
26. Lowenthal JW, York JJ, O'Neil TE, Rhodes S, Prowse SJ, Strom DG, and Digby MR: In vivo effects of chicken interferon-γ during infection with Eimeria. J Interferon Cytokine Res 1997;17:551-558.
27. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, Hayes D, Louder MK, Brown CR, Sapan CV, Frankel SS, Lu Y, Robb ML, Katinger H, and Birx DL: Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999;73:4009-4018.
28. O'Hagan DT, MacKichan ML, and Singh M: Recent developments in adjuvants for vaccines against infectious diseases. Biomol Eng 2001;18:69-85.
29. Oshop GL, Elankumaran S, and Heckert RA: DNA vaccination in the avian. Vet Immunol Immunopathol 2002;89:1-12.
30. Peeters BPH, de Leeuw OS, Koch G, and Gielkens AL: Rescue of Newcastle disease virus from cloned cDNA: Evidence that cleavability of the fusion protein is a major determinant for virulence. J Virol 1999;73:5001-5009.
31. Peppel K, and Baglioni C: A simple and fast method to extract RNA from tissue culture cells. Biotechniques 1990;9:711-713.
32. Phillips RJ, Samson AC, and Emmerson PT: Nucleotide sequence of the 5′-terminus of Newcastle disease virus and assembly of the complete genomic sequence: agreement with the "rule of six." Arch Virol 1998;143:1993-2002.
33. Rautenschlein S, Sharma JM, Winslow BJ, McMillen J, Junker D, and Cochran M: Embryo vaccination of turkeys against Newcastle disease infection with recombinant fowlpox virus constructs containing interferons as adjuvants. Vaccine 1999;18:426-433.
34. Reiner SL, Zheng S, Corry DB, and Locksley RM: Constructing polycompetitor cDNAs for quantitative PCR. J Immunol Methods 1993;165:37-46.
35. Roy P, Nachimuthu K, Koteeswaran A, Albert A, and Venugopalan AT: Postvaccinal immune response to regimens of Newcastle disease vaccination by filter paper sampling technique. Trap Anim Health Prod 1997;29:20-24.
36. Sakaguchi M, Nakamura H, Sonoda K, Hamada F, and Hirai K: Protection of chickens from Newcastle disease by vaccination with a linear plasmid DNA expressing the F protein of Newcastle disease virus. Vaccine 1996;14:747-752.
37. Scheerlinck JY: Genetic adjuvants for DNA vaccines. Vaccine 2001;19:2647-2656.
38. Umino Y, Kohama T, Kohase M, Sugiura A, Klenk HD, and Rott R: Protective effect of antibodies to two viral envelope glycoproteins on lethal infection with Newcastle disease virus. Arch Virol 1987;94:97-107.
39. Umino Y, Kohama T, Sato TA, and Sugiura A: Protective effect of monoclonal antibodies to Newcastle disease virus in passive immunization. J Gen Virol 1990;71:1199-1203.
40. Walz MK: [Minimally invasive adrenal gland surgery]. Chirurgie 1998;69:613-620.
41. Williams RA, Koroma MM, and Hodges M: Comparison of albendazole and levamisole chemotherapy on prevalence and intensity of common soil-transmitted helminth infections in school children, Sierra Leone. West Afr J Med 1997;16:179-183.
42. Wilson JA, and Hart MK: Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein. J Virol 2001;75:2660-2664.
43. Yamada K, Takasaki T, Nawa M, Yabe S, and Kurane I: Antibody responses determined for Japanese dengue fever patients by neutralization and hemagglutination inhibition assays demonstrate cross-reactivity between dengue and Japanese encephalitis viruses. Clin Diagn Lab Immunol 2003;10:725-728.
44. Zigterman GJ, Snippe H, Jansze M, and Willers JM: Adjuvant effects of nonionic block polymer surfactants on liposome-induced humoral immune response. J Immunol 1987;138:220-225.